
Sertraline Mechanism of Action Action Pathway (New)
Sertraline Mechanism of Action Pathway (New) References
Pastoor D, Gobburu J: Clinical pharmacology review of escitalopram for the treatment of depression. Expert Opin Drug Metab Toxicol. 2014 Jan;10(1):121-8. doi: 10.1517/17425255.2014.863873. Epub 2013 Nov 30.
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.
Rao N: The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet. 2007;46(4):281-90. doi: 10.2165/00003088-200746040-00002.
Florio V, Porcelli S, Saria A, Serretti A, Conca A: Escitalopram plasma levels and antidepressant response. Eur Neuropsychopharmacol. 2017 Sep;27(9):940-944. doi: 10.1016/j.euroneuro.2017.06.009. Epub 2017 Jun 23.
Singh HK, Saadabadi A: Sertraline.